Roche Receives the US FDA’s Approval for HPV Self-Collection Solutions for Cervical Cancer
Shots:
- Roche has received the US FDA’s approval for its human papillomavirus (HPV) self-collection solution with its cobas HPV test to detect cervical cancer at the earliest for the treatment
- The HPV self-collection solution works by screening vaginal samples from the individuals which are sent to labs for analysis through Roche’s cobas molecular instrument to detect if the patient is HPV positive or not for further treatment
- Additionally, Roche teamed up with the National Cancer Institute (NCI) for the Cervical Cancer “Last Mile” Initiative, facilitating the regulatory approval process
Ref: Roche | Image: Roche
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
